secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001193125-24-084937
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine bitopertin Phase 2 in EPP meets primary endpoint; key secondary misses significance
--------------------------------------------------------------------------------

- Primary endpoint met: PPIX reduced 21.6% (20mg, p=0.003) and 40.7% (60mg, p<0.001) vs placebo +8.0%.
- Key secondary (cumulative sunlight time) not significant: 175.1h (20mg), 153.1h (60mg) vs 133.9h placebo due to strong placebo response.
- Phototoxic reactions with pain reduced 75% for 60mg (p=0.011) and 60% for 20mg (p=0.109).
- Patient Global Impression of Change: 86% of 60mg completers rated 'much better' vs 50% placebo (p=0.022).
- Bitopertin well tolerated, no SAEs; dizziness most common AE; two discontinuations at 60mg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524084937/0001193125-24-084937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524084937/d815786d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-084937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer